Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Plovamer acetate dose-ranging study versus Copaxone in relapsing-remitting multiple sclerosis
2013-002283-25Phase 2Completed
- Sponsor
- Merck KGaA
- Start
- Sep 2013
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of plovamer acetate in relapsing-remitting multiple sclerosis (RRMS) (5 arms), sponsored by Merck KGaA. Primary endpoint: Mean number of T1 gadolinium-enhancing lesions per patient per scan. Started Sep 2013; status: completed.
02
Drugs
plovamer acetate
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on 2013-002283-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002283-25.